StreetInsider.com News Articles

Form 4 Zenas BioPharma, Inc. For: Jun 15 Filed by: Nunn Jason Raleigh

Wed, 17 Jun 2026 18:10:00 -0400

si-local-file:///var/storage/secattach/20260617/26661212.html

Form 4 Zenas BioPharma, Inc. For: Jun 15 Filed by: Nunn Jason Raleigh

Wed, 17 Jun 2026 18:10:00 -0400

si-local-file:///var/storage/secattach/20260617/26661212.html

Form 4 Zenas BioPharma, Inc. For: Jun 15 Filed by: ORLOFF JOHN J

Wed, 17 Jun 2026 18:03:00 -0400

si-local-file:///var/storage/secattach/20260617/26661177.html

Form 4 Zenas BioPharma, Inc. For: Jun 15 Filed by: ORLOFF JOHN J

Wed, 17 Jun 2026 18:03:00 -0400

si-local-file:///var/storage/secattach/20260617/26661177.html

Form 4 Zenas BioPharma, Inc. For: Jun 15 Filed by: MOULDER LEON O JR

Wed, 17 Jun 2026 18:03:00 -0400

si-local-file:///var/storage/secattach/20260617/26661178.html

Form 4 Zenas BioPharma, Inc. For: Jun 15 Filed by: MOULDER LEON O JR

Wed, 17 Jun 2026 18:03:00 -0400

si-local-file:///var/storage/secattach/20260617/26661178.html

Form 4 Zenas BioPharma, Inc. For: Jun 15 Filed by: Lu Hongbo

Wed, 17 Jun 2026 18:03:00 -0400

si-local-file:///var/storage/secattach/20260617/26661181.html

Form 4 Zenas BioPharma, Inc. For: Jun 15 Filed by: Lu Hongbo

Wed, 17 Jun 2026 18:03:00 -0400

si-local-file:///var/storage/secattach/20260617/26661181.html

Form 4 Zenas BioPharma, Inc. For: Jun 15 Filed by: Allen Patricia L

Wed, 17 Jun 2026 18:02:00 -0400

si-local-file:///var/storage/secattach/20260617/26661170.html

Form 4 Zenas BioPharma, Inc. For: Jun 15 Filed by: Allen Patricia L

Wed, 17 Jun 2026 18:02:00 -0400

si-local-file:///var/storage/secattach/20260617/26661170.html

Form 4 Zenas BioPharma, Inc. For: Jun 15 Filed by: von Moltke Lisa

Wed, 17 Jun 2026 18:02:00 -0400

si-local-file:///var/storage/secattach/20260617/26661172.html

Form 4 Zenas BioPharma, Inc. For: Jun 15 Filed by: von Moltke Lisa

Wed, 17 Jun 2026 18:02:00 -0400

si-local-file:///var/storage/secattach/20260617/26661172.html

Form 4 Zenas BioPharma, Inc. For: Jun 15 Filed by: Farmer Joseph L

Wed, 17 Jun 2026 18:01:00 -0400

si-local-file:///var/storage/secattach/20260617/26661155.html

Form 4 Zenas BioPharma, Inc. For: Jun 15 Filed by: Farmer Joseph L

Wed, 17 Jun 2026 18:01:00 -0400

si-local-file:///var/storage/secattach/20260617/26661155.html

Form 4 Zenas BioPharma, Inc. For: Jun 15 Filed by: ENRIGHT PATRICK G

Wed, 17 Jun 2026 18:01:00 -0400

si-local-file:///var/storage/secattach/20260617/26661159.html

Form 4 Zenas BioPharma, Inc. For: Jun 15 Filed by: ENRIGHT PATRICK G

Wed, 17 Jun 2026 18:01:00 -0400

si-local-file:///var/storage/secattach/20260617/26661159.html

Form 4 Zenas BioPharma, Inc. For: Jun 15 Filed by: Boylan James P

Wed, 17 Jun 2026 18:01:00 -0400

si-local-file:///var/storage/secattach/20260617/26661165.html

Form 4 Zenas BioPharma, Inc. For: Jun 15 Filed by: Boylan James P

Wed, 17 Jun 2026 18:01:00 -0400

si-local-file:///var/storage/secattach/20260617/26661165.html

Form 4 Zenas BioPharma, Inc. For: Jun 15 Filed by: Fox Jennifer A.

Wed, 17 Jun 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260617/26661152.html

Form 4 Zenas BioPharma, Inc. For: Jun 15 Filed by: Fox Jennifer A.

Wed, 17 Jun 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260617/26661152.html

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 17 Jun 2026 16:15:00 -0400

WALTHAM, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on June 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 100,000 shares of the Company’s common stock (“Stock Options”) and an aggregate of 78,075 restricted stock units of the Company’s common stock (“RSUs”) to newly hired employees of

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 17 Jun 2026 16:15:00 -0400

Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

Thu, 11 Jun 2026 16:15:00 -0400

WALTHAM, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced management’s presentation at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit. The presentation will be available on-demand beginning on Monday, June 15, 2026, at 7:00 a.m. ET.

A webcast and archived replay of the Company’s presentation can be accessed under “Events and Presentations” in the Investor &

Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

Thu, 11 Jun 2026 16:15:00 -0400

A webcast and archived replay of the Company’s presentation can be accessed under “Events and Presentations” in the Investor &

H.C. Wainwright Reiterates Buy Rating on Zenas Biopharma (ZBIO)

Wed, 03 Jun 2026 06:54:01 -0400

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $44.00 price target on Zenas Biopharma (NASDAQ: ZBIO).

The analyst commented: "On the heels of the announced BLA submission for bifunctional mAb CD19 and FcγRIIb inhibitor obexelimab, for the treatment of immunoglobulin G4-related disease (IgG4-RD), the company announced presentation of the full results from the successful Phase 3 INDIGO trial, which we view as consistent with obexelimab’s potential as a 1L therapy for the treatment of IgG4-RD. Importantly, the additional positive data from the EULAR 2026 Congress in London, England was concurrently published in the NEJM, highlighting that the positive Phase